BETABeta Drugs Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassWatch
Market Cap₹1,197 Cr
Primary DriverBalance Sheet Stress
Flagium AI Risk Score
Early signs of stress detected. Not yet widespread, but initial deterioration is visible.
24 / 100
+15 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in balance sheet stress. This suggests a building risk profile. Risk is increasing at a faster pace.

63.6th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
₹1,416.1▼0.51%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress
+13.5 pts
Growth Sustainability
+10.0 pts
Final Composite Risk24 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 24 over 12 quarters.

Expected Direction
🚨 Escalate
Primary Deterioration Drivers
  • Inventory Stress
  • Working Capital Expansion
What to Watch Next Quarter
  • Working capital efficiency
  • Inventory turnover

Active Risk Objects (2)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 3 Years
More Detail
Impact Weight10/15
MomentumPersistent
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 124.2%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ4 FY2026
Inventory growth (24.6%) significantly outpaced revenue growth (-48.2%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)47.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+42.0+47.0📈 CRITICAL
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,416.1(-0.51%)
1M Divergence+4.2%
1 Week+1.14%
1 Month+6.47%
6 Months-15.27%
1 Year-24.94%
2 Year+17.79%
3 Year+84.79%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The risk profile is Early Signals and currently deteriorating. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.

BETA • MARKET STRUCTURE

Stage 4 — Declining

The company is in a defensive phase. Sentiment and fundamentals are deteriorating under persistent downward pressure, indicating elevated risk levels.

Stage Transition Prob.0%
Trend QualityDeteriorating
Phase Progression
Phase Progression Score25%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing0%
CoinTree Momentum
Composite Z-Score+0.3137σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#587 of 2716
Top 21.61% in momentum strength
Timeframe Sparklines
1W+1.1%
1M+6.5%
6M-15.3%
Weinstein Indicators
150 DMA₹1,442.57
200 DMA₹1,540.84
150 DMA Slope-3.8941%Declining
Relative Strength-10.85%Lagging
Relative Turnover (RTR)1.7513
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

BETABeta Drugs Limited
24 Risk
Sector %ile64th
Delta+15
Active Flags2
Accel+1
Balance Sheet Stress

Watch

AARTIPHARMAarti Pharmalabs Limited
35 Risk
Sector %ile81th
Delta0
Active Flags18
Accel+0
Earnings Quality

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
3.232.5th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
00th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Working Capital Expansion

2026

Working Capital Expansion

2025

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20263964137148
FY20253694232133